Breaking Ground: The First Curative, Durable, Non-Surgical Therapy for Endometriosis

The contract seeks the development of a first-of-its-kind, non-surgical, curative therapy for endometriosis that fundamentally alters the disease course by eliminating or permanently deactivating endometrial implants without invasive procedures. The focus is on novel interventions that reduce lesion size, suppress the inflammatory response triggered by the implants, and prevent recurrence or regrowth, aiming for a durable solution that replaces the current standard of care centered on surgery and symptomatic management. Proposals must demonstrate a clear path toward a treatment that is not palliative but truly transformative, addressing the biological root causes of endometriosis rather than merely mitigating symptoms. This opportunity is issued under ARPA-H 04 by the Advanced Research Projects Agency for Health within the Department of Health and Human Services, and it is designated as a Total Small Business Set-Aside, meaning only small businesses with fewer than 500 employees are eligible to submit proposals under the SBIR/STTR mandate. The solicitation is classified under NAICS code 541714 for research and development in biotechnology, and the response deadline is set for September 30, 2027. The project is expected to yield a therapeutic intervention that significantly advances patient care by removing the need for surgical removal of lesions, thereby addressing the limitations and risks inherent in current treatment paradigms.